{
    "organizations": [],
    "uuid": "5c4173d821e3d24783739e4f5db39e8a0c403edf",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-myokardia-announces-positive-resul/brief-myokardia-announces-positive-results-from-phase-2-pioneer-hcm-study-of-mavacamten-idUSFWN1QQ0ZE",
    "ord_in_thread": 0,
    "title": "BRIEF-Myokardia Announces Positive Results From Phase 2 Pioneer-Hcm Study Of Mavacamten",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 8 (Reuters) - Myokardia Inc:\n* MYOKARDIA ANNOUNCES POSITIVE RESULTS FROM LOW-DOSE COHORT OF PHASE 2 PIONEER-HCM STUDY OF MAVACAMTEN IN SYMPTOMATIC, OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY PATIENTS\n* MYOKARDIA INC - STUDY MET PRIMARY ENDPOINT AND KEY SECONDARY ENDPOINTS WITH STATISTICAL SIGNIFICANCE\n* MYOKARDIA INC - STUDY RESULTS INFORM PHASE 3 EXPLORER-HCM DOSING; FIRST PATIENT PLANNED FOR Q2 2018 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-03-09T05:17:00.000+02:00",
    "crawled": "2018-03-09T14:10:39.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "myokardia",
        "inc",
        "myokardia",
        "announces",
        "positive",
        "result",
        "cohort",
        "phase",
        "study",
        "mavacamten",
        "symptomatic",
        "obstructive",
        "hypertrophic",
        "cardiomyopathy",
        "patient",
        "myokardia",
        "inc",
        "study",
        "met",
        "primary",
        "endpoint",
        "key",
        "secondary",
        "endpoint",
        "statistical",
        "significance",
        "myokardia",
        "inc",
        "study",
        "result",
        "inform",
        "phase",
        "dosing",
        "first",
        "patient",
        "planned",
        "q2",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}